Proactive Response to Domestic Cases
Establishment of National Surveillance System

The Korea Disease Control and Prevention Agency (KDCA) announced on March 27 that it will newly designate Candida auris infection as a Class 4 notifiable infectious disease and a healthcare-associated infection, effective from March 29.


Candida auris infection is a disease caused by the fungus Candida auris. Generally, Candida auris can be transmitted through contact between patients, contaminated medical devices or environments, and the hands of medical staff. In particular, because of its high resistance to antifungal agents and the risk of fatal outcomes in invasive infections among immunocompromised individuals, prompt diagnosis, appropriate treatment, and infection control are crucial.

Candida Auris Infection Newly Designated as a Class 4 Notifiable Infectious Disease View original image

The World Health Organization (WHO), in its 2022 "Fungal Priority Pathogens List," classified Candida auris as a top-tier risk group and an "antimicrobial resistance threat pathogen," emphasizing the importance of active response and core global strategies. The U.S. Centers for Disease Control and Prevention (CDC) has also designated it as an "urgent threat" pathogen, and it is widely recognized internationally as a significant public health threat.


In Korea, low-pathogenic, non-resistant Candida auris (Clade II) has generally been the main type identified. However, there have been continued reports of infections caused by highly pathogenic Candida auris (Clade I), highlighting the ongoing need to establish a national surveillance and management system.


With this new designation as a Class 4 infectious disease, Candida auris infections will be subject to case and pathogen carrier reporting and notification under the sentinel surveillance system. Surveillance will be centered around 368 sentinel institutions nationwide, allowing for more precise monitoring of occurrences within healthcare facilities. By applying health insurance coverage to isolation room hospitalization fees, the burden of isolation and treatment for both healthcare facilities and patients is expected to be alleviated.


The KDCA has established and distributed the "Candida auris Infection Control Guidelines" to strengthen the response capabilities in medical settings and has conducted training and public awareness activities for officials at local governments and healthcare institutions. The guidelines include operational standards for the surveillance system and practical, work-centered information that can be immediately used in healthcare facilities. In addition, treatment recommendations have been developed and distributed to support clinical decision-making, even in facilities without infection specialists on staff.



Im Seungkwan, Commissioner of the KDCA, stated, "The designation of Candida auris infection as a Class 4 infectious disease marks the beginning of a comprehensive national management system for multidrug-resistant fungal infections with high risk of spread in medical institutions. We will continue operating the surveillance system, accumulate domestic epidemiological data, and, based on this, further advance the frameworks for diagnosis, treatment, and infection control to enhance our ability to respond to healthcare-associated infections."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing